Seminars in Radiation Oncology
Volume 20, Issue 2 , Pages 130-137, April 2010

Adaptive Radiation Therapy for Prostate Cancer

  • Michel Ghilezan, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Michel Ghilezan, MD, PhD, Department of Radiation Oncology, William Beaumont Hospitals and Research Institute, Royal Oak, MI 48073-6769
  • ,
  • Di Yan, DSc
  • ,
  • Alvaro Martinez, MD

Department of Radiation Oncology, William Beaumont Hospitals and Research Institute, Royal Oak, MI

Adaptive radiotherapy has been introduced to manage an individual's treatment by, including patient-specific treatment variation identified and quantified during the course of radiotherapy in the treatment planning and delivering optimization. Early studies have demonstrated that this technique could significantly improve the therapeutic ratio by safely reducing the large target margin that has to be used in conventional radiotherapy for prostate cancer treatment. Clinical application of off-line image-guided adaptive radiotherapy for prostate cancer has demonstrated encouraging clinical outcome. Long-term clinical follow-up has shown significant improvement in terms of tumor control and low toxicity profile, emphasizing the beneficial effect of image-guidance and adaptive treatment. Continuous development in adaptive radiotherapy has made possible additional increases in target dose by further reducing target margin when using online image-guided adaptive intensity-modulated radiation therapy. However, clinical implementation of new techniques should be explored cautiously and should include a comprehensive management strategy to address uncertainties in target definition and delineation in the preclinical implementation studies.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Clinical translational research of adaptive radiotherapy for prostate cancer in Radiation Oncology, William Beaumont Hospitals has been supported in part by NCI, Grants: R29 CA71785, R01 CA118037, R01 CA091020, R21 CA130330, and US Army Medical Research, Grants: PC970201, PC061209.

 Department of Radiation Oncology in William Beaumont Hospital receives research and development grants from ELEKTA Oncological System and Philips Radiation Oncological System.

PII: S1053-4296(09)00081-2

doi:10.1016/j.semradonc.2009.11.007

Seminars in Radiation Oncology
Volume 20, Issue 2 , Pages 130-137, April 2010